PrimYuan Bio, a Pioneer in Live Biotherapeutic Products for Autoimmune Diseases, Files IPO Prospectus Following Over RMB 10 Million Series A Funding

Since 2017, China's probiotics market has been growing rapidly at a compound annual growth rate (CAGR) of 15%, and is projected to reach RMB 142 billion in 2023, accounting for more than 25% of the global market.

Although the total demand for probiotic products in China’s market is high, over 90% of probiotic products in the dietary supplement sector still rely on imports. Giants such as DuPont (USA) and Chr. Hansen (Denmark) dominate the Chinese market. Due to the late start of domestic enterprises, China lacks effective competing products, resulting in significant shortcomings.

According to Grand View Research, driven by policy support, technological breakthroughs, and capital infusion, the global live biotherapeutic products industry has entered a fast track of development since 2017, with no monopoly by major players yet established. Therefore,Live Biotherapeutic Products (LBPs) Become the “New Hotspot,” with Competition in the Sector Growing “Fierce”. It is now imperative to develop high-efficiency bacterial strains with independent intellectual property rights,“Localized Strains” May Become the Core Competitiveness of Domestic Enterprises。

According to VCBeat,One of the First Domestic Enterprises Dedicated to the R&D of Live Biotherapeutic Products for Autoimmune Diseases——Hangzhou Puyuan Biotechnology Co., Ltd.(hereinafter referred to as "Puyuan Biotechnology")Recently completed its first round of financing. This round of financing was led byXIN HUA CAI TONG Exclusive Investment，Investment Amount Exceeds 10 Million Yuan. Puyuan Biotechnology stated that the funds raised will be used for further functional development and clinical studies of its proprietary star strains, including PM002 and PM005; market development of its proprietary probiotic brand, Gibson; and the construction of a fermentation center.

Puyuan Biotechnology was established byProfessor Liang Qiming, Shanghai Jiao Tong University School of MedicineYuApril 2021Founded. Professor Liang Qiming graduated from Florida State University in the United States and completed his postdoctoral research at the University of Southern California, boasting over a decade of experience in biomedical research and development.Long-term commitment to mechanistic and translational research on immunity against microbial infections, with identification of multiple probiotic strains that regulate autoimmune diseases., and the research findings have been widely recognized internationally (Cell Stem Cell 2016, 2020; Med 2021; Nature Immunology 2022).

Under the leadership of Professor Liang Qiming, Puyuan BiotechnologyBased on microbiome research, focusing on the frontiers of neuroimmunology and gut microbiota, we engage in the R&D and production of probiotics and their products.. Currently, the company has mastered advanced technologies such as strain characterization and large-scale preparation, and employs membrane filtration of fermentation broth to achieve high-density fermentation and concentration. On the other hand, cold shock pretreatment and optimized cryoprotectants can enableProbiotic Freeze-Dried Survival Rate Reaches 95%，The concentration of viable bacteria reaches up to 10¹²CFU/g，"Reaching an internationally leading level"。

Building on in-depth research into the impact of gut microbiota on the immune system, the company utilizes microbial ecological preparations to modulate gut microbiota and regulate human immune homeostasis, thereby mastering a series of novel approaches for the prevention and treatment of autoimmune diseases.Currently, Puyuan Biotechnology has established a "localized" functional strain library, with a layout of over 10,000 microbial strains, among which more than 2,500 are proprietary strains with excellent characteristics., and filter out relevantInflammatory Bowel Disease、Multiple Sclerosis、Ankylosing Spondylitis、Tumor Immunology、DiabetesMultiple star strains for such indications.

Next, Puyuan Biotechnology will focus onAutoimmune Diseases, focusing on the probiotics industry,"Starting with Food and Foods for Special Medical Purposes (Health Supplements)"，Aiming to Develop and Manufacture Live Biotherapeutic Products for Clinical Applications, develop products that are novel, advanced, and unique, serve the national strategy of "Healthy China," and expand into domestic and international markets.

Yang Zhenhuan, Investment Director of Xinghua Dingli Biopharmaceutical“Live biotherapeutic products have broad applications and a vast market. The mechanisms underlying interactions among various human microbial species are continuously being elucidated, leading to a steady emergence of innovative achievements. With the approval of the world’s first fecal microbiota therapy at the end of last year, the live biotherapeutic industry is poised for explosive growth. Leveraging its extensive probiotic resource library and strong R&D capabilities, the team at Shenzhen Puyuan Biotechnology Co., Ltd. has independently developed several flagship strains targeting autoimmune diseases, with early experimental results proving highly encouraging. We remain firmly optimistic about the prospects of this field and the growth potential of Shenzhen Puyuan Biotechnology, and we look forward to seeing the company achieve steady, long-term success as a leading enterprise in the live biotherapeutic sector.”

Xinghua Dingli Venture Capital, established in 2022, is a professional venture capital firm specializing in the fields of biopharmaceuticals, new energy, and semiconductors. It is dedicated to identifying and supporting outstanding entrepreneurs who consistently create value. With assets under management amounting to hundreds of millions of yuan, Xinghua Dingli has invested in a portfolio of innovation-driven companies and was honored as one of the “2022 Zhejiang Emerging Venture Capital Institutions.”